Abstract
The S100A8/S100A9 heterodimer, commonly referred to as calprotectin (CP), is a member of the S100 subfamily of EF-hand calcium binding proteins that is largely expressed in activated monocytes and macrophages and has well-defined functions in acute and chronic inflammation. Indeed, certain S100 proteins including S100A8/A9 are exported from cells by an as-yet unknown mechanism. Once outside the cell, S100A8/A9 activates cell surface receptors such as the receptor for advanced glycation end products (RAGE) and has also been shown to inhibit the growth of pathogenic bacteria through the chelation of trace metal ions such as zinc (Zn2+) and manganese (Mn2+). The binding of these metal ions by S100A8/A9 has also been shown to induce apoptosis in various tumor cell lines. However, several lines of evidence have suggested that S100A8/A9-dependent apoptosis is not solely due to its ability to sequester Zn2+ from cells. Rather, it appears that trace metal binding to S100A8/A9 triggers a novel conformational switch in the protein, which promotes binding to specific sites on the surface of cells or through interaction with yet unidentified cell surface receptors. This review summarizes what is currently known regarding the molecular mechanisms by which S100A8/A9 performs its role as a novel apoptotic agent.
Keywords: S100A8/A9, calprotectin, apoptosis, zinc
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer
Volume: 8 Issue: 4
Author(s): Mohammad Hashemi, Seth Chitayat, Sudharsana Rao Ande and Walter J. Chazin
Affiliation:
Keywords: S100A8/A9, calprotectin, apoptosis, zinc
Abstract: The S100A8/S100A9 heterodimer, commonly referred to as calprotectin (CP), is a member of the S100 subfamily of EF-hand calcium binding proteins that is largely expressed in activated monocytes and macrophages and has well-defined functions in acute and chronic inflammation. Indeed, certain S100 proteins including S100A8/A9 are exported from cells by an as-yet unknown mechanism. Once outside the cell, S100A8/A9 activates cell surface receptors such as the receptor for advanced glycation end products (RAGE) and has also been shown to inhibit the growth of pathogenic bacteria through the chelation of trace metal ions such as zinc (Zn2+) and manganese (Mn2+). The binding of these metal ions by S100A8/A9 has also been shown to induce apoptosis in various tumor cell lines. However, several lines of evidence have suggested that S100A8/A9-dependent apoptosis is not solely due to its ability to sequester Zn2+ from cells. Rather, it appears that trace metal binding to S100A8/A9 triggers a novel conformational switch in the protein, which promotes binding to specific sites on the surface of cells or through interaction with yet unidentified cell surface receptors. This review summarizes what is currently known regarding the molecular mechanisms by which S100A8/A9 performs its role as a novel apoptotic agent.
Export Options
About this article
Cite this article as:
Hashemi Mohammad, Chitayat Seth, Ande Rao Sudharsana and Chazin J. Walter, Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (4) . https://dx.doi.org/10.2174/187152309789838993
DOI https://dx.doi.org/10.2174/187152309789838993 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anesthetic Cardioprotection: The Role of Adenosine
Current Pharmaceutical Design Cerebral Amyloid Angiopathy: A Common Cause of Cerebral Hemorrhage
Current Medicinal Chemistry Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Strategies Targeting Endothelial Function in Humans:Clinical Implications
Current Vascular Pharmacology Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology Complement System in SLE as a Target for Antibodies
Current Rheumatology Reviews Systemic Inflammation Induces Endothelial Dysfunction in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Proteostasis, an Emerging Therapeutic Paradigm for Managing Inflammatory Airway Stress Disease
Current Molecular Medicine Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Neutrophil-Derived Cytokines: Potential Therapeutic Targets in Inflammation
Current Drug Targets - Inflammation & Allergy Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design The Relationship Between Social Support, Social Constraint, and Psychological Adjustment for Patients with Rare Autoimmune Disease
Current Rheumatology Reviews Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Commentary: Perivascular Fat and Improved Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology